Average duration of fever (body temperature over 37.0 С) (according to the patient's diary). [ Time Frame: 7(± 1) days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Dynamics of the clinical manifestations of ARI according to the objective medical examination (summary score of the CCQ scale at first, third and seventh days of treatment) [ Time Frame: 7(± 1) days ] [ Designated as safety issue: No ]

Suspected initial manifestations of diseases that have symptoms similar to ARI (other infectious diseases, flu-like symptoms at the onset of systemic connective tissue disorders, oncohematological and other pathologies).

Exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in a clinical trial.

Oncological diseases.

Medical history of polyvalent allergy.

Allergy / intolerance to any of the components of medications used in the treatment.

Impaired glucose tolerance, diabetes mellitus type 1 and 2.

Hereditary fructose intolerance (due to the presence of maltitol in the examined medicine).

Intake of medicines listed in the section "Prohibited concomitant treatment" for 1 month prior to participation in the trial.

Pregnancy, breast feeding.

Drugs usage, alcohol usage in the amount over 2 units of alcohol per day.

Patients with mental disorders.

Patients, who from investigator's point of view will fail to comply with the observation requirements of the trial or with the intake regimen of the investigated medicines.

Participation in other clinical trials in the course of 3 months prior to inclusion into the present trial.

Other factors, which hinder the patient's participation in the trial (for example, planned trips or business trips).

The patient is related to the research personnel of the centre who are directly involved in the trial or are the immediate family of the researcher. The immediate family includes husband / wife, parents, children or brothers / sisters, regardless of whether they are natural or adopted.

The patient works for OOO "NPF "Materia Medica Holding", i.e. s/he is the company's employee, temporary contract worker, and designated official responsible for carrying out the research or their immediate family.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01765920